MedTrace Logo

Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia

NCT00709215 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2009-01-09

No results posted yet for this study

Summary

This is a two-part, open-label, Phase I/II study in subjects with relapsed or refractory TdT-positive leukemia for which no standard therapies are expected to result in durable remission.

Conditions

  • Refractory TdT-Positive Leukemia

Interventions

DRUG

Cordycepin plus Pentostatin

Cordycepin Plus Pentostatin on days 1, 2 and 3 of a 21 day cycle. Number of cycles until progression or unacceptable toxicity

Sponsors & Collaborators

  • AAIPharma

    collaborator INDUSTRY

  • OncoVista, Inc.

    lead INDUSTRY

Principal Investigators

  • Swaminathan Padmanabhan, MD · Cancer Therapy Research Center at UTHSCSA

  • Daneil J DeAngelo, MD, PhD. · Dana Farber Cancr Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00709215 on ClinicalTrials.gov